

1. A compound of the formula I or II

NE

in which

- is hydrogen, branched and unbranched C_1 - C_6 -alkyl, it also being possible for one C atom of the alkyl radical to carry OR^{11} or a group R^5 , where R^{11} is hydrogen or C_1 - C_4 -alkyl, and
- is hydrogen, chlorine, bromine, iodine, fluorine, CF₃, nitro, NHCOR²¹, NR²²R²³0H, O-C₁-C₄-alkyl, O-C₁-C₄-alkylphenyl, NH₂, phenyl, it also being possible for the phenyl rings to be substituted by at most two radicals R²⁴, and R²¹ and R²² independently of one another are hydrogen or C₁-C₄-alkyl and R²³ is hydrogen, C₁-C₄-alkyl or phenyl, and R²⁴ is OH, C₁-C₆-alkyl, O-C₁-C₄-alkyl, chlorine, bromine, iodine, fluorine, CF₃, nitro, NH₂, and
- x may be 0, 1 or 2 and
- R^3 is $-D-(F^1)_p-(E)_q-(F^2)_r$ -G, where p, q and r may not simultaneously be 0, or is -E- $(D)_u-(F^2)_s-(G)_v$, it also being possible for the radical E to be substituted by one or two radicals A, and if v=0, E is imidazole, pyrrole, pyridine, pyrimidine, piperazine, pyrazine, pyrrolidine or piperidine, or R^3 is B and

- is hydrogen, chlorine, fluorine, bromine, iodine, branched and unbranched C_1 - C_6 -alkyl, OH, nitro, CF_3 , CN, $NR^{41}R^{42}$, NH-CO- R^{43} , O- C_1 - C_4 -alkyl, where R^{41} and R^{42} independently of one another are hydrogen or C_1 - C_4 -alkyl and R^{43} is hydrogen, C_1 - C_4 -alkyl, C_1 - C_4 -alkylphenyl or phenyl, and
- D is S or O
- E is phenyl, imidazole, pyrrole, thiophene, pyridine, pyrimidine, piperazine, pyrazine, furan, thiazole, isoxazole, pyrrolidine, piperidine, trihydroazepine and
- is a chain of 1 to 8 carbon atoms, it also being possible for one carbon atom of the chain to carry an OH or O-C₁-C₄-alkyl group and
- F² is a chain of 1 to 8 carbon atoms, it also being possible for one carbon atom of the chain to carry an OH or O-C₁-C₄-alkyl group and
- p may be 0 or 1
- q may be 0 or 1, and
- r may be 0 or 1 and
- s may be 0 or 1
- u may be 0 or 1
- v may be 0 or 1
- G may be NR⁵¹R⁵² or

and

R⁵¹ is hydrogen or branched and unbranched C₁-C₆-alkyl, (CH₂)_t-K and

R⁵² is hydrogen, branched and unbranched CI-C6-alkyl, phenyl,

$$R^{53}$$
, -SO₂R⁵³, -(C=N)-R⁵³, -C=N)-NHR⁵³

in which

 R^{53} may be branched or unbranched O-C₁-C₆-alkyl, phenyl, branched or unbranched C₁-C₄-alkylphenyl, where in the case of R^{52} and R^{53} independently of one another one hydrogen of the C₁-C₆-alkyl radical may be substituted by one of the following radicals: OH, O-C₁-C₄-alkyl, cyclohexyl, cyclopentyl, tetrahydronaphthyl, cyclopropyl, cyclobutyl, cycloheptyl, naphthyl and phenyl, it also being possible for the carbocycles of the radicals R^{52} and R^{53} independently of one another to carry one or two of the following radicals: branched or unbranched C₁-C₆-alkyl, branched or unbranched O-C₁-C₄-alkyl,

OH, F, C1, Br, I, CF₃, NO₂, NH₂, CN, COOH, COOC₁-C₄-alkyl, C₁-C₄-alkylamino, CC1₃, C₁-C₄-dialkylamino, SO₂-C₁-C₄- alkyl, SO₂phenyl, CONH₂, CONH-C₁-C₄-alkyl, CONHphenyl, CONH-C₁-C₄-alkylphenyl, NHSO₂-C₁-C₄-alkyl, NHSO₂phenyl, S-C₁-C₄-alkyl, alkyl,

$$-0 \xrightarrow{C_1-C_4-alkyl, -0} \xrightarrow{C_0-C_4-alkylphenyl,}$$

CHO, CH_2 -O- C_1 - C_4 -alkyl, - CH_2 O- C_1 - C_4 -alkylphenyl, - CH_2 OH, -SO- C_1 - C_4 -alkylphenyl, - SO_2 NH- C_1 - C_4 -alkyland two radicals form a bridge -O- $(CH_2)_{1,2}$ -O-,

B may be

and

- may be hydrogen, chlorine, bromine, iodine, fluorine, CF_3 , nitro, OH, $O-C_1-C_4$ -alkyl, $O-C_1-C_4$ -alkylphenyl, NH_2 , branched and unbranched C_1-C_6 -alkyl, CN, $NH-CO-R^{33}$, where R^{33} is hydrogen, C_1-C_4 -alkyl or phenyl and
- R³¹ is hydrogen, C₁-C₆-alkyl, (CH₂)_t-K and
- R^{32} is hydrogen, C_1 - C_6 -alkyl, -CO- R^8 , SO_2 - R^8 , -(C=N)= R^8 -CO-NHR⁸, -CO-OR⁸ and (C=N)-NHR⁸ and
- R³³ is hydrogen and C₁-C₄-alkyl and
- t is 0,1,2,3,4 and
- is phenyl which may carry at most two radicals R, is $NR^{k1}R^{k2}$ (where R^{k1} and R^{k2} are as defined for R^{41} and R^{42} respectively), $NH-C_1-C_4$ -alkylphenyl, pyrrolidine, piperidine, 1,2, 5, 6-tetrahydropyridine, morpholine, trihydroazepine, piperazine, which may also be substituted by an alkyl radical C_1-C_6 -alkyl, and homopiperazine, which may also be substituted by an alkyl radical C_1-C_6 -alkyl, and
- R⁵ may be hydrogen, C₁-C₆-alkyl, NR₇R₉ and

and

- R^7 is hydrogen, C_1 - C_6 -alkyl, C_1 - C_4 -alkylphenyl, phenyl, it also being possible for the rings to be substituted by up to two radicals R^{71} , and
- R⁷¹ is OH, C₁-C₆-alkyl, O-C₁-C₄-alkyl, chlorine, bromine, iodine, fluorine, CF₃, nitro, NH₂, and
- R⁸ is hydrogen, C_1 - C_6 -alkyl, phenyl, C_1 - C_4 -alkylphenyl, it also being possible for the ring to be substituted by up to two radicals R⁸¹, and
- R^{81} is OH, C_1 - C_6 -alkyl, O- C_1 - C_4 -alkyl, chlorine, bromine, iodine, fluorine, CF_{3} , nitro, NH_2 and
- is hydrogen, COCH₃, CO-O-C₁-C₄-alkyl, COCF₃, branched and unbranched C₁-C₆-alkyl, it being possible for one or two hydrogens of the C₁-C₆-alkyl radical to be substituted in each case by one of the following radicals: OH, O-C₁-C₄-alkyl and phenyl, and for the phenyl ring also to carry one or two of the following radicals: iodine, chlorine, bromine, fluorine, branched and unbranched C₁-C₆-alkyl, nitro, amino, C₁-C₄-alkylamino, C₁-C₄-dialkylamino, OH, O-C₁-C4-alkyl, CN, CF₃, SO₂-C₁-C₄-alkyl,

and the tautomeric forms, possible enantiomeric and diastereomeric forms thereof, the prodrugs thereof and pharmacologically tolerated salts.



- 2. A compound of the formula I or II as claimed in claim 1 in which
- R¹ is hydrogen, branched and unbranched C₁-C₆-alkyl, it also being possible for one C atom of the alkyl radical to carry OR¹¹ or a group R⁵, where

CLEAN COPY OF CLAIMS OZ 49500

R¹¹ is hydrogen or C₁-C₄-alkyl, and

is hydrogen, chlorine, fluorine, bromine, iodine, branched and unbranched C₁-C₆-alkyl, nitro, CF₃, CN, NR²¹R²², NH-CO-R²³, OR²¹, where

R²¹ and R²² are, independently of one another, hydrogen or C₁-C₄-alkyl, arid

R²³ is hydrogen, C₁-C₄-alkyl or phenyl, and

 R^3 is -O-(CH₂)₀-(CHR³)_m-(CH₂)_n-R⁵, where

R³¹ is hydrogen, C₁-C₄-alkyl, OH and O-C₁-C₄-alkyl,

m,o are, independently of one another, 0, 1 or 2, and

n is 1, 2, 3 or 4 and

 R^4 is hydrogen, branched and unbranched C_1 - C_6 -alkyl, chlorine, bromine, fluorine, nitro, cyano, $NR^{41}R^{42}$ NH-CO- R^{43} OR⁴¹ where

R⁴¹ and R⁴² are, independently of one another, hydrogen or C₁-C₄-alkyl, and

 R^{43} is C_1 - C_4 -alkyl or phenyl, and

R⁵ is NR⁵¹R⁵² or one of the following radicals

where

R⁵¹ is hydrogen and branched and unbranched C₁-C₆-alkyl, and

R⁵² is hydrogen, branched and unbranched C₁-C₆-alkyl phenyl, and

$$\mathbb{R}^{53}$$
, $-SO_2\mathbb{R}^{53}$, in which

 R^{53} is branched or unbranched O-C₁-C₆-alkyl, phenyl, branched or unbranched C₁-C₄-alkyl-phenyl, where one hydrogen in the C₁-C₆-alkyl radical in R^{52} and R^{53} can, independently of one another, be substituted by one of the following radicals: OB, O-C₁-C₄-alkyl, cyclohexyl, cyclopentyl, tetrahydronaphthyl, cyclopropyl, cyclobutyl, cycloheptyl, naphthyl and phenyl, where the carbocycles of the R^{52} and R^{53} radicals may also, independently of one another, carry one or two of the following radicals: branched or unbranched C_1 -C₆-alkyl, branched or unbranched O-C₁-C₄-alkyl, OH, F, C1, Br, I, CF₃, NO₂, NH₂, CN, COOH, COOC₁-C₄-alkyl, C_1 -C₄-alkylamino, CC1₃, C_1 -C₄-dialkylamino, SO₂-C₁-C₄-alkyl, C_1 -C₄-alkyl, C_1 -C₄-alky

CHO, CH_2 -O- C_1 - C_4 -alkyl, $-CH_2O$ - C_1 - C_4 -alkyl-phenyl, $-CH_2OH$, -SO- C_1 - C_4 -alkyl-phenyl, SO_2NH_2 , $-SO_2NH$ - C_1 - C_4 -alkyl and two radicals form a bridge -O- $(CH_2)_{1,2}$ -O-,

and the tautomeric form, possible enantiomeric and diastereomeric forms thereof, the prodrugs thereof, and possible physiologically tolerated salts.

- 3. A compound of the formula I or II as claimed in claim 1 in which
 - is hydrogen, branched and unbranched C₁-C₆-alkyl, it also being possible for one C atom of the alkyl radical to carry OR¹¹ or a group R⁵, where
 - R¹¹ is hydrogen or C₁-C₄-alkyl, and
 - is hydrogen, chlorine, fluorine, bromine, iodine, branched and unbranched C₁-C₆-alkyl, nitro, CF₃, CN, NR²¹R²², NH-CO-R²³, OR²¹, where
 - R^{21} and R^{22} independently of one another are hydrogen or $C_1\text{-}C_4\text{-alkyl}$ and

0 | 0 4 am s

R³ is

and

 R^{31} is hydrogen, CHO and $-(CH_2)_o-(CHR^{32})_m-(CH_2)_n-R^5$, where R^{32} is

hydrogen, C_1 - C_4 -alkyl, OH and O- C_1 - C_4 -alkyl, m,o independently of one another are 0, 1 or 2 and n is 1, 2, 3 or 4, and

 R^4 is hydrogen, branched and unbranched C_1 - C_6 -alkyl, chlorine, bromine, fluorine, nitro, cyano, $NR^{41}R^{42}$ NH-CO- R^{43} , OR^{41} , where

R41 and R42 independently of one another are hydrogen or C1-C4-alkyl and

R⁴³ is C₁-C₄-alkyl or phenyl, and

R⁵ is NR⁵¹R⁵² or one of the radicals below

where


is hydrogen and branched and unbranched and C₁-C₆-alkyl and is hydrogen, COCH₃, CO-O-C₁-C₄-alkyl, COCF₃, branched and unbranched C₁-C₆-alkyl, it being possible for one hydrogen of the C₁-C₆-alkyl radical to be substituted by one of the following radicals: OH, O-C₁-C₄-alkyl and phenyl and for the phenyl ring also to carry one or two of the following radicals: chlorine, bromine, fluorine, branched and unbranched C₁-C₄-alkyl, nitro, amino, C₁-C₄-alkylamino, C₁-C₄-dialkylamino, OH, O-C₁-C₄-alkyl, CN, SO₂-C₁-C₄-alkyl,

and the tautomeric forms, possible enantiomeric and diastereomeric forms thereof, the prodrugs thereof, and possible physiologically tolerated salts.

- 4. A compound as claimed in claim 1, where R² is in position 3 and R³ is in position 4 or R² is in position 4 and R³ is in position 3 relative to the benzimidazole ring.
- 5. A compound as claimed in claim 1, where R¹ and R⁴ are hydrogen.
- 6. A compound as claimed in claim 1, where
 - R^2 is hydrogen, branched or unbranched C_1 - C_6 -alkyl, nitro, CN, NH₂, O-C₁- C_4 -alkyl.

A compound as claimed in claim 1 where

for R³ being



- R^{31} is hydrogen or $-(CH_2)_p-R^5$, where
- p is 1 or 2 and
- may be hydrogen, branched and unbranched C_1 C_6 -alkyl, where one hydrogen of the C_1 - C_6 -alkyl radical may be substituted by one of the following radicals: OH, O- C_1 - C_4 -alkyl and phenyl, and where the phenyl

ring may also carry one or two of the following radicals: chlorine, bromine, fluorine, branched and unbranched C₁₋C₄-alkyl, nitro, amino, C₁-C₄alkylamino, C₁-C₄- dialkylamino, OH, O-C₁-C₄-alkyl, CN, SO₂-C₁-C₄-alkyl;

for R³ being (ii)

is hydrogen or -(CH₂)_p-R⁵, where R^{31}

is 1 or 2 and р

 R^{52} may be hydrogen, branched and unbranched C₁-C₆-alkyl, where one hydrogen of the C_1 - C_6 -alkyl radical may be substituted by one of the following radicals: OH, O-C₁-C₄(alkyl and phenyl, and where the phenyl ring may also carry one or two of the following radicals: chlorine, bromine, fluorine, branched and unbranched C₁-C₄-alkyl, nitro, amino, C₁-C₄alkylamino, C_1 - C_4 - dialkylamino, OH, $O-C_1$ - C_4 -alkyl, CN, SO_2 - C_1 - C_4 -alkyl; and (iii) for R3 being

where R^{52} is hydrogen, branched and unbranched C_1 - C_6 -alkyl, where one hydrogen of the C_1 - C_6 -alkyl radical may be substituted by one of the following radicals: OH, $O-C_1-C_4$ -alkyl and phenyl, and where the phenyl ring may also carry one or two of the following radicals: chlorine, bromine, fluorine, branched and unbranched C_1-C_4 -alkyl, nitro, amino, C_1-C_4 -alkylamino, C_1-C_4 -dialkylamino, OH, $O-C_1-C_4$ -alkyl, CN, $SO_2-C_1-C_4$ -alkyl.

- 8. A compound as claimed in claim 1, where R^3 is $-O-(CH_2)_p-R^5$ with p equal to 2, 3 or 4.
- 9. A compound as claimed in claim 1, where R⁵ is a 6-membered ring and R⁵² is an optionally substituted phenyl ring.
- A drug comprising besides conventional vehicles and ancillary substances a compound as claimed in claim 1.
- 11. A method for treating a disorder in which pathologically elevated PARP activities occur, said method comprising administering an effective amount of a compound of the formula I as claimed in claim 1 to a mammal suffering from said disorder.
- 12. The method as claimed in claim 11 wherein the disorder is a neurodegenerative disease or involves neuronal damage.
- 13. The method as claimed in claim 12, wherein the neurodegenerative disease or neuronal damage is induced by ischemia, trauma or massive bleeding.
- 14. The method as claimed in claim 11 wherein the disorder is stroke and


CLEAN COPY OF CLAIMS OZ 49500 craniocere ral trauma.

- 15. The method as claimed in claim 11 wherein the disorder is Alzheimer's disease and Huntington's disease.
- 16. The method as claimed in claim 11 wherein the disorder is damage due to ischemia.
- 17. The method as claimed in claim 11 wherein the disorder is epilepsy.
- 18. The method as claimed in claim 11 wherein the disorder is damage to the kidneys after renal ischemia, damage caused by drug therapy or damage resulting after kidney transplants.
- 19. The method as claimed in claim 11 wherein the disorder is damage to the heart after cardiac ischemia.
- 20. The method as claimed in claim 11 wherein the disorder is a microinfarct.
- 21. The method as claimed in claim 11 wherein the disorder is under vascularization of critically narrowed coronary arteries.
- 22. The method as claimed in claim 11 wherein the disorder is an acute myocardial infarct and damage during and after medical or mechanical lysis thereof.
- 23. The method as claimed in claim 11 wherein the disorder is a tumor or metastasis I thereof.
- 24. The method as claimed in claim 11 wherein the disorder is sepsis of multi-organ failure.
- 25. The method as claimed in claim 11 wherein the disorder is an immunological

disease.

- 26. The method as claimed in claim 11 wherein the disorder is diabetes mellitus.
- 27. A compound of the formula XX or XXI

AZ Cont'd



in which

 R^4 = hydrogen and R^1 is defined in claim 1, and salts thereof.

28. A process for preparing compounds of the formula XX or XXI as claimed in claim 27 and salts thereof, which comprises converting the corresponding ester into the amide XX or XXI with hydrazine hydrate in an alcohol and subsequent reduction of the hydrazine with Raney nickel in a polar solvent.

CLAIM 29 IS CANCELED

- 30. An in vitro detection method for PARP inhibitors, which comprises
 - incubating an unsupported or supported polyADP-ribosylatable target with a reaction mixture comprising
 - a1) a PARP
 - a2) a PARP activator; and
 - a3) a PARP inhibitor or an analyte in which at least one PARP inhibitor is suspected

16

- b) carrying out the polyADP-ribosylation reaction: and
- c) determining the polyADP-ribosylation of the target qualitatively or quantitatively using an anti-poly(ADP-ribose) antibody.
- 31. A method as claimed in claim 30, wherein PARP is preincubated with the PARP activator and the PARP inhibitor or an analyte in which at least one PARP inhibitor is suspected before the polyADP ribosylation reaction is carried out.
- 32. A method as claimed in either of claims 30 or 31, wherein the polyADP-ribosylatable target is a histone protein.
- 33. A method as chaimed in any of claims 30 to 32, wherein the PARP activator is activated DNA.
- 34. A method as claimed in any of claims 30 to 33, wherein the polyADP ribosylation reaction is started by adding NAD+.
- 35. A method as claimed in any of claims 30 to 34, wherein the unsupported target is labeled with an acceptor fluorophore.
- 36. A method as claimed in claim 35, wherein the polyADP ribosylation of the unsupported target is determined using anti-poly(ADP-ribose) antibody which is labeled with a donor fluorophore which is able to transfer energy to the acceptor fluorophore.
- 37. A method as claimed in either of claims 35 or 36, wherein the target is biotinylated histone, and the acceptor fluorophore is coupled thereto via avidin or streptavidin.
- 38. A method as claimed in either of claims 36 and 37, wherein the anti-poly(ADP-

ribose) antibody carries a europium cryptate as donor fluorophore.